Ozcan Yildiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ozcan Yildiz has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Bilici
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
7 shared publications - Harun Muğlu
Istanbul Medipol University, Turkey (Türkiye)
7 shared publications - Jamshid Hamdard
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
7 shared publications - Omer Fatih Olmez
Faculty of Medicine, Medical Oncology Department, Medipol University, İstanbul, Türkiye, Turkey (Türkiye)
7 shared publications - Özgür Açıkgöz
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
7 shared publications - Oktay Olmuşçelik
Department of Internal Medicine, Istanbul Medipol University, 34810 Istanbul, Türkiye
4 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by MDPI AG in Preprints.org
The Prognostic Role of Systemic Inflammatory Markers Before Abiraterone/Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer
Objective: To investigate the prognostic value of systemic inflammatory markers (SIM)—namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ra-tio (PLR)—on survival outcomes and treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone (ABI) or enzalu-tamide (ENZA) therapy. Methods: This two-center retrospective observational study analyzed clinical data of 106 patients diagnosed with mCRPC. The cut-off values for NLR and PLR were deter-mined as 2.83 and 156, respectively. Their effects on progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. Changes in SIM before and after ABI/ENZA treatment were assessed using the Wilcoxon signed-rank test. Results: Lower NLR (≤2.83) and PLR (≤156) levels were significantly associated with longer PFS and OS. In multivariate analysis, only high PLR emerged as an independent adverse prognostic factor for OS (HR: 2.01; p=0.026). Treatment response was an inde-pendent predictor of PFS. No significant changes were observed in MPV, PDW, or P-LCR levels after treatment. Conclusion: SIM such as NLR and especially PLR may serve as practical and accessible tools for predicting survival in mCRPC patients. However, further prospective studies are warranted.
- 4 August 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Prognostic Role of Systemic Inflammatory Markers Before Abiraterone/Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer
Objective: To investigate the prognostic value of systemic inflammatory markers (SIM)—namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ra-tio (PLR)—on survival outcomes and treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone (ABI) or enzalu-tamide (ENZA) therapy. Methods: This two-center retrospective observational study analyzed clinical data of 106 patients diagnosed with mCRPC. The cut-off values for NLR and PLR were deter-mined as 2.83 and 156, respectively. Their effects on progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. Changes in SIM before and after ABI/ENZA treatment were assessed using the Wilcoxon signed-rank test. Results: Lower NLR (≤2.83) and PLR (≤156) levels were significantly associated with longer PFS and OS. In multivariate analysis, only high PLR emerged as an independent adverse prognostic factor for OS (HR: 2.01; p=0.026). Treatment response was an inde-pendent predictor of PFS. No significant changes were observed in MPV, PDW, or P-LCR levels after treatment. Conclusion: SIM such as NLR and especially PLR may serve as practical and accessible tools for predicting survival in mCRPC patients. However, further prospective studies are warranted.
- Open Access
- 21 April 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (8) , 1048
The Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy
Background/Objectives: This study investigated the prognostic and predictive significance of Ataxia–Telangiectasia Mutated (ATM) expression in patients with metastatic non-small-cell lung cancer (NSCLC) who were treated with pembrolizumab. Methods: A retrospective analysis was conducted on 49 patients with metastatic NSCLC who received first-line pembrolizumab, either as a single agent or in combination with chemotherapy. ATM expression in archival pathology specimens was assessed using immunohistochemistry, where nuclear staining was considered to be positive. ATM expression was categorized into low- and high-expression groups based on staining intensity and the percentage of positive cells. Subsequently, the prognostic and predictive value of ATM expression was evaluated. Results: In terms of demographics, the mean age was 62.7 ± 9.5, most patients (91.8%) were male, and the majority (75.5%) had adenocarcinoma. The objective response rate (ORR) was 69.4%, and ATM expression was high in 75.5% of patients. Patients with low ATM expression had significantly longer progression-free survival (PFS) compared to those with high expression (51 vs. 5.7 months, p = 0.004). In multivariate analysis, ATM expression was the only independent prognostic factor for PFS, showing that patients with high ATM expression had a shorter overall survival (OS) compared to those with low expression (51 vs. 8.9 months, p = 0.013), which was statistically significant (HR 2.41, p = 0.034). Logistic regression analysis showed that ATM expression, as well as the presence of bone metastasis and the absence of liver metastasis, was significantly associated with a response to treatment (p = 0.006; OR: 0.06; 95% CI: 0.008–0.45). Conclusions: The findings of this study concerning ATM expression as a biomarker should be interpreted cautiously due to inherent limitations, including its retrospective design, the semi-quantitative nature of immunohistochemistry for ATM assessment, the small sample size with uneven clinical characteristics, and the relatively short follow-up period, which collectively impact generalizability. Despite these limitations, lower ATM expression was associated with better prognosis and pembrolizumab treatment response, suggesting that it may be a valuable biomarker for predicting these factors.
- 21 April 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (8) , 1048
Open AccessThe Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy
Background/Objectives: This study investigated the prognostic and predictive significance of Ataxia–Telangiectasia Mutated (ATM) expression in patients with metastatic non-small-cell lung cancer (NSCLC) who were treated with pembrolizumab. Methods: A retrospective analysis was conducted on 49 patients with metastatic NSCLC who received first-line pembrolizumab, either as a single agent or in combination with chemotherapy. ATM expression in archival pathology specimens was assessed using immunohistochemistry, where nuclear staining was considered to be positive. ATM expression was categorized into low- and high-expression groups based on staining intensity and the percentage of positive cells. Subsequently, the prognostic and predictive value of ATM expression was evaluated. Results: In terms of demographics, the mean age was 62.7 ± 9.5, most patients (91.8%) were male, and the majority (75.5%) had adenocarcinoma. The objective response rate (ORR) was 69.4%, and ATM expression was high in 75.5% of patients. Patients with low ATM expression had significantly longer progression-free survival (PFS) compared to those with high expression (51 vs. 5.7 months, p = 0.004). In multivariate analysis, ATM expression was the only independent prognostic factor for PFS, showing that patients with high ATM expression had a shorter overall survival (OS) compared to those with low expression (51 vs. 8.9 months, p = 0.013), which was statistically significant (HR 2.41, p = 0.034). Logistic regression analysis showed that ATM expression, as well as the presence of bone metastasis and the absence of liver metastasis, was significantly associated with a response to treatment (p = 0.006; OR: 0.06; 95% CI: 0.008–0.45). Conclusions: The findings of this study concerning ATM expression as a biomarker should be interpreted cautiously due to inherent limitations, including its retrospective design, the semi-quantitative nature of immunohistochemistry for ATM assessment, the small sample size with uneven clinical characteristics, and the relatively short follow-up period, which collectively impact generalizability. Despite these limitations, lower ATM expression was associated with better prognosis and pembrolizumab treatment response, suggesting that it may be a valuable biomarker for predicting these factors.
- Open Access
- 26 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2264
Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience
Background/Objectives: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies with no standardized treatment approach. Although platinum-based chemotherapy is considered the first-line therapy, overall survival (OS) and progression-free survival (PFS) remain limited. This study aims to evaluate the clinical and pathological characteristics of EP-NEC patients, their treatment responses, and survival outcomes. Methods: This retrospective observational study included 29 EP-NEC patients diagnosed and followed between 2015 and 2024. Clinical and demographic data, tumor localization, disease stage, administered treatments, and survival outcomes were analyzed. Kaplan–Meier survival analysis was used to assess OS and PFS, with subgroup comparisons performed via the log-rank test. Results: The most common primary tumor sites were the pancreas (21%), prostate (17%), and cervix (14%). At diagnosis, 55.2% of patients had metastatic disease. First-line platinum-based chemotherapy achieved an objective response rate of 82.1%, with a median PFS of 8.16 months and a median OS of 14.16 months. Surgical intervention significantly improved survival (p = 0.020), while a high Ki-67 proliferation index (>80%) was associated with worse PFS (p = 0.032). Other factors, including smoking status and liver-directed therapies, had no significant impact on survival. Conclusions: EP-NECs present with a poor prognosis despite platinum-based chemotherapy achieving high response rates. Surgical resection improves survival outcomes, whereas high Ki-67 expression is associated with a worse prognosis. These findings highlight the need for further research into novel therapeutic strategies for EP-NECs.
- 26 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2264
Open AccessClinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience
Background/Objectives: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies with no standardized treatment approach. Although platinum-based chemotherapy is considered the first-line therapy, overall survival (OS) and progression-free survival (PFS) remain limited. This study aims to evaluate the clinical and pathological characteristics of EP-NEC patients, their treatment responses, and survival outcomes. Methods: This retrospective observational study included 29 EP-NEC patients diagnosed and followed between 2015 and 2024. Clinical and demographic data, tumor localization, disease stage, administered treatments, and survival outcomes were analyzed. Kaplan–Meier survival analysis was used to assess OS and PFS, with subgroup comparisons performed via the log-rank test. Results: The most common primary tumor sites were the pancreas (21%), prostate (17%), and cervix (14%). At diagnosis, 55.2% of patients had metastatic disease. First-line platinum-based chemotherapy achieved an objective response rate of 82.1%, with a median PFS of 8.16 months and a median OS of 14.16 months. Surgical intervention significantly improved survival (p = 0.020), while a high Ki-67 proliferation index (>80%) was associated with worse PFS (p = 0.032). Other factors, including smoking status and liver-directed therapies, had no significant impact on survival. Conclusions: EP-NECs present with a poor prognosis despite platinum-based chemotherapy achieving high response rates. Surgical resection improves survival outcomes, whereas high Ki-67 expression is associated with a worse prognosis. These findings highlight the need for further research into novel therapeutic strategies for EP-NECs.
- Open Access
- 25 March 2025
- Published by MDPI AG in Preprints.org
The Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy
Background/Objectives: This study aimed to investigate the prognostic and predictive significance of ATM expression in patients with metastatic non-small cell lung cancer (NSCLC) treated with pembrolizumab. Methods: A retrospective analysis was conducted on 49 patients with metastatic NSCLC who received first-line pembrolizumab as a single agent or in combination with chemotherapy. Immunohistochemistry was used to assess ATM expression in archival pathology specimens. Nuclear staining was considered positive. ATM expression was categorized into low and high groups based on a combined score of staining intensity and percentage of positive cells. Therafter, prognostic and predictive value of ATM expression was evaluated. Results: The median age was 64 years (range, 45-81). Most patients (91.8%) were male. The majority of patients (75.5%) had adenocarcinoma. The objective response rate (ORR) was 69.4%. ATM expression was high in 75.5% of patients. Patients with low ATM expression had significantly longer progression-free survival (PFS) compared to those with high expression (51 vs. 5.7 months, p=0.004). In multivariate analysis, ATM expression was the only independent prognostic factor for PFS. Moreover, patients with high ATM expression had significantly shorter overall survival (OS) compared to those with low expression (51 vs. 8.9 months, p=0.013), as was statistically significant in multivariate analysis (HR 2.48, p=0.041). Logistic regression analysis showed that ATM expression was significantly associated with response to treatment (p=0.006, OR:0.16, 95% CI: 0.08-0.48), as were the presence of bone metastasis and absence of liver metastasis Conclusions: Our findings showed that lower ATM expression was associated with better prognosis and better pembrolizumab treatment response. This suggests that ATM expression may be a valuable biomarker for predicting disease progression and treatment response.
- 25 March 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy
Background/Objectives: This study aimed to investigate the prognostic and predictive significance of ATM expression in patients with metastatic non-small cell lung cancer (NSCLC) treated with pembrolizumab. Methods: A retrospective analysis was conducted on 49 patients with metastatic NSCLC who received first-line pembrolizumab as a single agent or in combination with chemotherapy. Immunohistochemistry was used to assess ATM expression in archival pathology specimens. Nuclear staining was considered positive. ATM expression was categorized into low and high groups based on a combined score of staining intensity and percentage of positive cells. Therafter, prognostic and predictive value of ATM expression was evaluated. Results: The median age was 64 years (range, 45-81). Most patients (91.8%) were male. The majority of patients (75.5%) had adenocarcinoma. The objective response rate (ORR) was 69.4%. ATM expression was high in 75.5% of patients. Patients with low ATM expression had significantly longer progression-free survival (PFS) compared to those with high expression (51 vs. 5.7 months, p=0.004). In multivariate analysis, ATM expression was the only independent prognostic factor for PFS. Moreover, patients with high ATM expression had significantly shorter overall survival (OS) compared to those with low expression (51 vs. 8.9 months, p=0.013), as was statistically significant in multivariate analysis (HR 2.48, p=0.041). Logistic regression analysis showed that ATM expression was significantly associated with response to treatment (p=0.006, OR:0.16, 95% CI: 0.08-0.48), as were the presence of bone metastasis and absence of liver metastasis Conclusions: Our findings showed that lower ATM expression was associated with better prognosis and better pembrolizumab treatment response. This suggests that ATM expression may be a valuable biomarker for predicting disease progression and treatment response.
- Open Access
- 3 March 2025
- Published by MDPI AG in Preprints.org
Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes- Single-Center Experience
Background: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies with no standardized treatment approach. Although platinum-based chemotherapy is considered the first-line therapy, overall survival (OS) and progression-free survival (PFS) remain limited. This study aims to evaluate the clinical and pathological characteristics of EP-NEC patients, their treatment responses, and survival outcomes. Methods: This retrospective observational study included 29 EP-NEC patients diagnosed and followed between 2015 and 2024. Clinical and demographic data, tumor localization, disease stage, administered treatments, and survival outcomes were analyzed. Kaplan-Meier survival analysis was used to assess OS and PFS, with subgroup comparisons performed via the log-rank test. Results: The most common primary tumor sites were the pancreas (21%), prostate (17%), and cervix (14%). At diagnosis, 55.2% of patients had metastatic disease. First-line platinum-based chemotherapy achieved an objective response rate of 82.1%, with a median PFS of 8.16 months and a median OS of 14.16 months. Surgical intervention significantly improved survival (p = 0.020), while a high Ki-67 proliferation index (>80%) was associated with worse PFS (p = 0.032). Other factors, including smoking status and liver-directed therapies, had no significant impact on survival. Conclusion: EP-NECs present with poor prognosis despite platinum-based chemotherapy achieving high response rates. Surgical resection improves survival outcomes, whereas high Ki-67 expression is associated with worse prognosis. These findings highlight the need for further research into novel therapeutic strategies for EP-NECs.
- 3 March 2025
- Published by MDPI AG in Preprints.org
Open AccessClinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes- Single-Center Experience
Background: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies with no standardized treatment approach. Although platinum-based chemotherapy is considered the first-line therapy, overall survival (OS) and progression-free survival (PFS) remain limited. This study aims to evaluate the clinical and pathological characteristics of EP-NEC patients, their treatment responses, and survival outcomes. Methods: This retrospective observational study included 29 EP-NEC patients diagnosed and followed between 2015 and 2024. Clinical and demographic data, tumor localization, disease stage, administered treatments, and survival outcomes were analyzed. Kaplan-Meier survival analysis was used to assess OS and PFS, with subgroup comparisons performed via the log-rank test. Results: The most common primary tumor sites were the pancreas (21%), prostate (17%), and cervix (14%). At diagnosis, 55.2% of patients had metastatic disease. First-line platinum-based chemotherapy achieved an objective response rate of 82.1%, with a median PFS of 8.16 months and a median OS of 14.16 months. Surgical intervention significantly improved survival (p = 0.020), while a high Ki-67 proliferation index (>80%) was associated with worse PFS (p = 0.032). Other factors, including smoking status and liver-directed therapies, had no significant impact on survival. Conclusion: EP-NECs present with poor prognosis despite platinum-based chemotherapy achieving high response rates. Surgical resection improves survival outcomes, whereas high Ki-67 expression is associated with worse prognosis. These findings highlight the need for further research into novel therapeutic strategies for EP-NECs.
- Open Access
Prognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer
Background and Objectives: Epithelial ovarian cancer (EOC) remains a significant global health challenge. While traditional prognostic factors are well established, emerging biomarkers continue to gain attention. Materials and Methods: This retrospective study evaluated the impact of systemic inflammatory markers on progression-free survival (PFS) and overall survival (OS) in 154 EOC patients. Pre-treatment neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and systemic inflammatory index (SII) were calculated and categorized into low and high groups. Univariate and multivariate analyses were conducted to identify independent prognostic factors, while logistic regression analysis was used to determine predictors of platinum resistance. Results: In the univariate analysis, elevated NLR and PLR were associated with poorer PFS and OS. However, these markers did not maintain statistical significance in the multivariate analysis. Although SII demonstrated a trend toward worse outcomes, it did not reach statistical significance. Histopathological type, PLR, and surgical approach were identified as independent predictors of platinum resistance. Conclusions: Our findings indicate that systemic inflammatory markers may hold prognostic value in EOC; however, further validation through larger prospective studies is necessary.
Open AccessPrognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer
Background and Objectives: Epithelial ovarian cancer (EOC) remains a significant global health challenge. While traditional prognostic factors are well established, emerging biomarkers continue to gain attention. Materials and Methods: This retrospective study evaluated the impact of systemic inflammatory markers on progression-free survival (PFS) and overall survival (OS) in 154 EOC patients. Pre-treatment neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and systemic inflammatory index (SII) were calculated and categorized into low and high groups. Univariate and multivariate analyses were conducted to identify independent prognostic factors, while logistic regression analysis was used to determine predictors of platinum resistance. Results: In the univariate analysis, elevated NLR and PLR were associated with poorer PFS and OS. However, these markers did not maintain statistical significance in the multivariate analysis. Although SII demonstrated a trend toward worse outcomes, it did not reach statistical significance. Histopathological type, PLR, and surgical approach were identified as independent predictors of platinum resistance. Conclusions: Our findings indicate that systemic inflammatory markers may hold prognostic value in EOC; however, further validation through larger prospective studies is necessary.
- Open Access
- 26 December 2024
- Published by MDPI AG in Preprints.org
Prognostic And Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) remains a significant health burden globally. While traditional prognostic factors are well-established, newer biomarkers are emerging. This retrospective study aimed to investigate the impact of systemic inflammatory markers on progression-free survival (PFS) and overall survival (OS) in 154 EOC patients. Pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammatory index (SII) were calculated and categorized into low and high groups. Univariate and multivariate analyses were performed to identify independent prognostic factors. Logistic regression analysis was used to determine predictors of platinum resistance. Elevated NLR and PLR were associated with poorer PFS and OS in univariate analysis. However, these markers did not retain their significance in multivariate analysis. SII showed a trend towards worse outcomes but did not reach statistical significance. Histopathological type, PLR, and surgical type were identified as independent predictors of platinum resistance. Our findings suggest that systemic inflammatory markers may have prognostic value in EOC, but further validation in larger prospective studies is warranted.
- 26 December 2024
- Published by MDPI AG in Preprints.org
Open AccessPrognostic And Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) remains a significant health burden globally. While traditional prognostic factors are well-established, newer biomarkers are emerging. This retrospective study aimed to investigate the impact of systemic inflammatory markers on progression-free survival (PFS) and overall survival (OS) in 154 EOC patients. Pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammatory index (SII) were calculated and categorized into low and high groups. Univariate and multivariate analyses were performed to identify independent prognostic factors. Logistic regression analysis was used to determine predictors of platinum resistance. Elevated NLR and PLR were associated with poorer PFS and OS in univariate analysis. However, these markers did not retain their significance in multivariate analysis. SII showed a trend towards worse outcomes but did not reach statistical significance. Histopathological type, PLR, and surgical type were identified as independent predictors of platinum resistance. Our findings suggest that systemic inflammatory markers may have prognostic value in EOC, but further validation in larger prospective studies is warranted.
- 25 March 2014
- Vol. 19 (1) , 97-102
What is the optimal treatment in clinical stage T3N0M0 rectal cancer?
Some previous studies suggested that certain rectal cancer patients with stage T3N0 and favorable features may be adequately treated with surgery and adjuvant chemotherapy. However, the optimal management of clinical (c) T3N0 rectal adenocarcinoma based on preoperative imaging is unclear. In this study, we aimed to determine the frequency of lymph node metastases in patients clinically staged as T3N0 rectal adenocarcinoma following preoperative chemoradiotherapy (CTR). The medical records of 105 patients with clinico- imaging stage T3N0M0 rectal cancer who received preoperative CRT between 2004-2011 were retrospectively analyzed. Chemotherapy used concurrently with preoperative radiotherapy (RT) was protracted 5-fluorouracil (5FU) infusion. Twenty-seven percent of the patients clinically staged as T3N0 before preoperative CRT had pathological (p) lymph node involvement on surgical material. The rate of pathological lymph node involvement was 0% in pT1, 20% in pT2 , 35% in pT3 and 34% in pT4 patients. A significant association was demonstrated between pT stages and pN status (p=0.03). Our study demonstrated that the accuracy of preoperative imaging for staging rectal cancer is limited because at least 27% of the patients may have undetected lymph node involvement after preoperative CRT in surgical material.
- 25 March 2014
- Vol. 19 (1) , 97-102
What is the optimal treatment in clinical stage T3N0M0 rectal cancer?
Some previous studies suggested that certain rectal cancer patients with stage T3N0 and favorable features may be adequately treated with surgery and adjuvant chemotherapy. However, the optimal management of clinical (c) T3N0 rectal adenocarcinoma based on preoperative imaging is unclear. In this study, we aimed to determine the frequency of lymph node metastases in patients clinically staged as T3N0 rectal adenocarcinoma following preoperative chemoradiotherapy (CTR). The medical records of 105 patients with clinico- imaging stage T3N0M0 rectal cancer who received preoperative CRT between 2004-2011 were retrospectively analyzed. Chemotherapy used concurrently with preoperative radiotherapy (RT) was protracted 5-fluorouracil (5FU) infusion. Twenty-seven percent of the patients clinically staged as T3N0 before preoperative CRT had pathological (p) lymph node involvement on surgical material. The rate of pathological lymph node involvement was 0% in pT1, 20% in pT2 , 35% in pT3 and 34% in pT4 patients. A significant association was demonstrated between pT stages and pN status (p=0.03). Our study demonstrated that the accuracy of preoperative imaging for staging rectal cancer is limited because at least 27% of the patients may have undetected lymph node involvement after preoperative CRT in surgical material.
- 1 September 2013
- Vol. 60 (126) , 1365-70
The relation between pathological complete response and clinical outcome in patients with rectal cancer.
Preoperative chemoradiotherapy (CRT) is the standard treatment modality in locally advanced rectal cancer. The primary aim was to correlate pathological complete response (pCR) with patient outcome, and the secondary objective was to identify predictive factors of pCR. Patients with clinical stage II/III rectal cancer who received preoperative CRT between 2002 and 2010 were retrospectively studied.The median radiotherapy dose was 54 Gy (range, 45 to 64 Gy), and all patients received concurrent infusional 5-fluorouracil-based chemotherapy. Median follow-up time was 48.3 months (range, 24 to 96 months) and 51 months (range, 44 to 110 months) for no-pCR and pCR groups, respectively. Eighteen patients (18.6%) had pCR. The 5-year overall survival was 95% for patients with pCR and 74.8% in patients without pCR (p=0.009). The 5-year local relapse free survival was 87.5% and 95% for the no-pCR and pCR groups, respectively (p=0.09). The 5-year distant relapse free survival was 93% in pCR group and 79.8% in no-pCR group (p=0.02). The 5-year distant free survival was 94% and 66% in patients with and without pCR, respectively (p=0.017). The clinical T4 (p=0.043) and pretreatment carcinoembryonic antigen level (CEA) >5ng/mL (p=0.012) were significantly associated with a lower pCR rate. In the multivariate logistic regression analysis, pretreatment CEA level >5ng/mL (p=0.008) was the only independent factor associated with a lower pCR rate. Patients with pCR after preoperative CRT had a significantly improved outcome. Furthermore, the pretreatment CEA level was independently associated with pCR.
- 1 September 2013
- Vol. 60 (126) , 1365-70
The relation between pathological complete response and clinical outcome in patients with rectal cancer.
Preoperative chemoradiotherapy (CRT) is the standard treatment modality in locally advanced rectal cancer. The primary aim was to correlate pathological complete response (pCR) with patient outcome, and the secondary objective was to identify predictive factors of pCR. Patients with clinical stage II/III rectal cancer who received preoperative CRT between 2002 and 2010 were retrospectively studied.The median radiotherapy dose was 54 Gy (range, 45 to 64 Gy), and all patients received concurrent infusional 5-fluorouracil-based chemotherapy. Median follow-up time was 48.3 months (range, 24 to 96 months) and 51 months (range, 44 to 110 months) for no-pCR and pCR groups, respectively. Eighteen patients (18.6%) had pCR. The 5-year overall survival was 95% for patients with pCR and 74.8% in patients without pCR (p=0.009). The 5-year local relapse free survival was 87.5% and 95% for the no-pCR and pCR groups, respectively (p=0.09). The 5-year distant relapse free survival was 93% in pCR group and 79.8% in no-pCR group (p=0.02). The 5-year distant free survival was 94% and 66% in patients with and without pCR, respectively (p=0.017). The clinical T4 (p=0.043) and pretreatment carcinoembryonic antigen level (CEA) >5ng/mL (p=0.012) were significantly associated with a lower pCR rate. In the multivariate logistic regression analysis, pretreatment CEA level >5ng/mL (p=0.008) was the only independent factor associated with a lower pCR rate. Patients with pCR after preoperative CRT had a significantly improved outcome. Furthermore, the pretreatment CEA level was independently associated with pCR.
- 5 June 2012
- Published by IntechOpen
Gastrointestinal Neuroendocrine Tumors